^
    Back
    Association details:
    Biomarker:TMB-H
    Cancer:Urothelial Cancer
    Drug:Imfinzi (durvalumab) (PD-L1 inhibitor) +
    fexagratinib (ABSK091) (FGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO 2019
    Title:

    An adaptive, biomarker directed platform study in metastatic urothelial cancer (BISCAY) with durvalumab in combination with targeted therapies

    Published date:
    09/28/2019
    Excerpt:
    TMB high for Arm E; 38% (Vistusertib + durvalumab) vs 5% in Arm A (AZD4547 + durvalumab), 20% in AZD4547 arm and 17% in Arm D; durvalumab). D monotherapy (n = 29) had an ORR of 28%, Vistusertib + durvalumab (21%), AZD4547 + durvalumab (39%), and AZD4547 (20%).